1. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C. & Aparicio, S. A. J. R. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
2. Hause, R. J., Pritchard, C. C., Shendure, J. & Salipante, S. J. Classification and characterization of microsatellite instability across 18 cancer types. Nat. Med. 22, 1342–1350 (2016).
3. Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A. & Jaffee, E. M. Targeting neoantigens to augment antitumour immunity. Nat. Rev. Cancer 17, 209–222 (2017).
4. Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500–2501 (2017).
5. Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (80-. ). 357, 409–413 (2017).
6. Lemery, S., Keegan, P. & Pazdur, R. First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication. N. Engl. J. Med. 337, 1409– 1412 (2017).
7. Lauss, M. et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat. Commun. 8, 1–11 (2017).
8. Rosenberg, S. A., Spiess, P. & Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (80-. ). 233, 1318–1321 (1986).
9. Topalian, S. L., Muul, L. M., Solomon, D. & Rosenberg, S. A. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods 102, 127–141 (1987).
10. Rosenberg, S. A. et al. Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma. N. Engl. J. Med. 319, 1676–1680 (1988).
11. Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J. & Rosenberg, S. A. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26, 332–42 (2008).
12. Dudley, M. E. et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346–2357 (2005).
13. Dudley, M. E. et al. Adoptive Cell Therapy for Patients With Metastatic Melanoma : Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. J. Clin. Oncol. 26, 5233–5239 (2008).
14. Besser, M. J. et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16, 2646–2655 (2010).
15. Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4557 (2011).
16. Radvanyi, L. G. et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 18, 6758–6770 (2012).
17. Besser, M. J. et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin. Cancer Res. 19, 4792–4800 (2013).
18. Goff, S. L. et al. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J. Clin. Oncol. 34, 2389–2397 (2016).
19. Andersen, R. et al. Long-Lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin. Cancer Res. 22, 3734–3745 (2016).
20. Tran, E. et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer. Science (80-. ). 344, 641–646 (2014).
21. Tran, E. et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N. Engl. J. Med. 375, 2255–2262 (2016).
22. Stevanović, S. et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science (80-. ). 356, 200– 205 (2017).
23. Zacharakis, N. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat. Med. 24, 724–730 (2018).
24. Dafni, U. et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: A systematic review and meta-analysis. Annals of Oncology vol. 30 1902–1913 (2019).
25. Itzhaki, O. et al. Establishment and large-scale expansion of minimally cultured ‘young’ tumor infiltrating lymphocytes for adoptive transfer therapy. J. Immunother. 34, 212–220 (2011).
26. Robbins, P. F. et al. Cutting Edge: Persistence of Transferred Lymphocyte Clonotypes Correlates with Cancer Regression in Patients Receiving Cell Transfer Therapy. J. Immunol. 173, 7125–7130 (2004).
27. Dudley, M. E. et al. CD8+ enriched ‘Young’ tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin. Cancer Res. 16, 6122–6131 (2010).
28. Zhou, J. et al. Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy. J. Immunol. 175, 7046–7052 (2005).
29. Butler, M. O. et al. Establishment of antitumor memory in humans using in vitro- educated CD8+ T cells. Sci. Transl. Med. 3, (2011).
30. Crompton, J. G. et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 75, 296–305 (2015).
31. Takahashi, K. & Yamanaka, S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell 126, 663–676 (2006).
32. Takahashi, K. et al. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell 131, 861–872 (2007).
33. Seki, T. et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating t cells. Cell Stem Cell 7, 11–13 (2010).
34. Loh, Y. H. et al. Reprogramming of T cells from human peripheral blood. Cell Stem Cell 7, 15–19 (2010).
35. Staerk, J. et al. Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell 7, 20–24 (2010).
36. Seki, T., Yuasa, S. & Fukuda, K. Generation of induced pluripotent stem cells from a small amount of human peripheral blood using a combination of activated T cells and Sendai virus. Nat. Protoc. 7, 718–728 (2012).
37. Vizcardo, R. et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8+ T cells. Cell Stem Cell 12, 31–36 (2013).
38. Nishimura, T. et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12, 114–126 (2013).
39. Miyoshi, H. & Stappenbeck, T. S. In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture. Nat. Protoc. 8, 2471–2482 (2013).
40. Miyoshi, H. et al. An improved method for culturing patient-derived colorectal cancer spheroids. Oncotarget 9, 21950–21964 (2018).
41. Turcotte, S. et al. Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy. J. Immunol. 191, 2217–2225 (2013).
42. Hall, M. L. et al. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J. Immunother. Cancer 4, 1–12 (2016).
43. Lee, H. J. et al. Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer. Oncotarget 8, 113345–113359 (2017).
44. Savas, P. et al. Single-cell profiling of breast cancer T cells reveals a tissue- resident memory subset associated with improved prognosis. Nat. Med. 24, (2018).
45. Datar, I. et al. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis. Clin. Cancer Res. 25, 4663–4673 (2019).
46. Friese, C. et al. CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer. Sci. Rep. 10, 1–12 (2020).
47. Rosenberg, S. A. et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86, 1159–1166 (1994).
48. Santegoets, S. J. A. M. et al. IL-21 promotes the expansion of CD27+CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J. Transl. Med. 11, 1–10 (2013).
49. Liu, Z. et al. Tumor-infiltrating lymphocytes (TILs) from patients with glioma. Oncoimmunology 6, (2017).
50. Tavera, R. J. et al. Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor- infiltrating Lymphocytes (TIL) Expansion: The Advantage over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma. J. Immunother. 41, 399–405 (2018).
51. Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature (2018) doi:10.1038/s41586-018- 0130-2.
52. Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25, 89–94 (2019).
53. Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537–1544 (2009).
54. Ye, Q. et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin. Cancer Res. 20, 44–55 (2014).
55. Betts, M. R. et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281, 65– 78 (2003).
56. Wolfl, M. et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110, 201–210 (2007).
57. Saito, H., Okita, K., Chang, A. E. & Ito, F. Adoptive transfer of CD8+ T cells generated from induced pluripotent stem cells triggers regressions of large tumors along with immunological memory. Cancer Res. 76, 3473–3483 (2016).
58. Maeda, T. et al. Regeneration of CD8αβ T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity. Cancer Res. 76, 6839–6850 (2016).
59. Minagawa, A. et al. Enhancing T Cell Receptor Stability in Rejuvenated iPSC- Derived T Cells Improves Their Use in Cancer Immunotherapy. Cell Stem Cell 23, 850-858.e4 (2018).
60. Saito, H. et al. Reprogramming of melanoma tumor-infiltrating lymphocytes to induced pluripotent stem cells. Stem Cells Int. 2016, (2016).
61. Yasui, Y., Hitoshi, Y. & Kaneko, S. In Vitro Differentiation of T Cell: From Human iPS Cells in Feeder-Free Condition. Methods Mol. Biol. 2048, 77–80 (2019).
62. Iriguchi, S. et al. A clinically applicable and scalable method to regenerate T- cells from iPSCs for off-the-shelf T-cell immunotherapy. Nat. Commun. 12, 1–15 (2021).
63. Ueda, N. et al. Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-Mediated Anti-leukemic Cell Response. Stem Cell Reports 10, 1935–1946 (2018).
64. Menk, A. V. et al. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J. Exp. Med. 215, jem.20171068 (2018).
65. Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science (80-. ). 350, 1387–1391 (2015).
66. Chatani, P. D. & Yang, J. C. Mutated RaS: Targeting the “untargetable” with T cells. Clin. Cancer Res. 26, 537–544 (2020).
67. Dijkstra, K. K. et al. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell 0, 1–13 (2018).
68. Miyazaki, K. et al. The transcription factor E2A activates multiple enhancers that drive Rag expression in developing T and B cells. Sci. Immunol. 5, (2020).
69. Maekawa, H. et al. A chemosensitivity study of colorectal cancer using xenografts of patient-derived tumor-initiating cells. Mol. Cancer Ther. 17, 2187– 2196 (2018).
70. Etxeberria, I. et al. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. Cancer Cell 36, 613–629 (2019).
論文の公開元へ
